SummaryRMgm-1431
|
Successful modification | The gene/parasite could not be changed/generated by the genetic modification. |
The following genetic modifications were attempted | Gene disruption |
Number of attempts to introduce the genetic modification | Unknown |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 23599312 |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
Attempts to generate the mutant parasite were performed by | |
Name PI/Researcher | Pulcini S; Tewari R; Krishna S |
Name Group/Department | Division of Clinical Sciences |
Name Institute | St. George's, University of London |
City | London |
Country | UK |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0207000 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0106300 | ||||||||||||||||||||||||
Gene product | calcium-transporting ATPase | ||||||||||||||||||||||||
Gene product: Alternative name | ATP6; SERCA; ATPase6 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Unknown | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | unknown | ||||||||||||||||||||||||
Promoter of the selectable marker | unknown | ||||||||||||||||||||||||
Selection (positive) procedure | unknown | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | Unsuccessful attempts to disrupt or tag this gene indicates an essential role of ATP6 (SERCA) for growth/multiplication of blood stages. Limited information is provided in the paper on the genetic modification attempts: "Similarly, a double recombination construct failed to KO pbserca in the more tractable Plasmodium berghei system, and C-terminal tagging was also unsuccessful (data not shown). Also attempts to disrupt/tag the P. falciparum ortholog were unsuccessful. ATP6 is the only SERCA-type Ca2+-ATPase sequence in the Plasmodium genome. The protein is thought to be a P-type ATPase involved in calcium ion transport. Mutations in this gene has been related to artemisinin-resistance of malaria parasites but results from several studies indicate that PfATP6 is not directly involved in artemisinin action or resistance. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |